TRICARIX SIGNED
Minimally invasive transcatheter system for tricuspid heart valve replacement
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0TRICARIX project word cloud
Explore the words cloud of the TRICARIX project. It provides you a very rough idea of what is the project "TRICARIX" about.
Project "TRICARIX" data sheet
The following table provides information about the project.
| Coordinator |
TRICARES GMBH
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 4˙346˙250 € |
| EC max contribution | 2˙477˙362 € (57%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-12-01 to 2021-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | TRICARES GMBH | DE (ASCHHEIM) | coordinator | 2˙477˙362.00 |
Map
Project objective
TRiCares is a medical technology company with the mission to develop and commercialize innovative minimally invasive (transcatheter) solutions replacing high-risk open-heart surgeries for treatment of heart valve diseases. Heart valve diseases are among the most serious cardiac complications affecting >12.7 million patients in Europe. Cardiac surgeons are urgently seeking for a low-risk minimally invasive solution to treat annually >300,000 patients with tricuspid heart valve disease, who are currently simply dying because of having no relevant therapeutic option. TRiCares has uniquely addressed technological challenges associated with tricuspid heart valve disease treatment- the company has developed the first-of-its-kind medical device for tricuspid heart valve replacement (TRICARIX) based on a proprietary dual-stent prosthesis platform. The product addresses a fast-growing transcatheter heart valve replacement/repair market, that is driven by the increasing demand to treat heart valve diseases in the aging population. As no such solution is available for tricuspid valve, introduction of the TRICARIX will create a novel market segment with estimated total market potential of €1 billion in Europe only. The company’s strategy has been built along the regulatory route to obtain CE-marking for the TRICARIX medical device in 2021. TRiCares is led by experienced entrepreneur and experts with successful track record of bringing medical devices to market, including the first European transcatheter aortic valve replacement system in 2012. TRiCares seeks SMEInstr funding to reach the critical First-In-Man study milestone (total costs-of the project €4.3 million) that will greatly facilitate follow-up capital investments to finance the final large-scale efficacy/safety clinical study. CE-marking will position the product/company for a licensing agreement with a global medical device company to ensure effective marketing and clinical implementation of the device.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRICARIX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRICARIX" are provided by the European Opendata Portal: CORDIS opendata.